Filing Details
- Accession Number:
- 0001209191-22-043920
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-02 17:04:34
- Reporting Period:
- 2022-08-01
- Accepted Time:
- 2022-08-02 17:04:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1108109 | Community Health Systems Inc | CYH | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1018660 | T Wayne Smith | 4000 Meridian Boulevard Franklin TN 37067 | Executive Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-01 | 200,000 | $3.00 | 3,259,196 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2022-08-02 | 800,000 | $2.94 | 4,059,196 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,606,842 | Indirect | by 2009 WTS Irrevocable Trust Dated 2/27/09 |
| Common Stock | 481,721 | Indirect | WAC LLC |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance Based Restricted | $0.00 | 225,000 | 225,000 | Direct | ||
| Common Stock | Performance Based Restricted | $0.00 | 180,000 | 180,000 | Direct | ||
| Common Stock | Performance Based Restricted | $0.00 | 180,000 | 180,000 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $4.99 | 2020-03-01 | 2029-02-28 | 78,750 | 78,750 | Direct |
| Common Stock | Stock Options (Right to Buy) | $4.93 | 2021-03-01 | 2030-02-28 | 112,500 | 112,500 | Direct |
| Common Stock | Stock Options (Right to Buy) | $8.81 | 2022-03-01 | 2031-02-28 | 90,000 | 90,000 | Direct |
| Common Stock | Stock Options (Right to Buy) | $10.18 | 2023-03-01 | 2032-02-29 | 90,000 | 90,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 225,000 | 225,000 | Direct | |
| 180,000 | 180,000 | Direct | |
| 180,000 | 180,000 | Direct | |
| 2029-02-28 | 78,750 | 78,750 | Direct |
| 2030-02-28 | 112,500 | 112,500 | Direct |
| 2031-02-28 | 90,000 | 90,000 | Direct |
| 2032-02-29 | 90,000 | 90,000 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price of $2.94 per share. These shares were purchased in multiple transactions on 08/02/2022 at prices ranging from $2.90 to $3.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2020 and 12/31/2022 (the "2020-2022 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2020-2022 Performance Period.
- The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2021 and 12/31/2023 (the "2021-2023 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2021-2023 Performance Period.
- The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2022-2024 Performance Period.
- Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
Billionaire Hedge Funds
